A study published in Neurology International found fusion rates of 98.6 percent with Orthofix's Trinity Elite cellular bone allograft, the devicemaker said Dec. 22.
Reserachers examined 201 patients over 12 months who had posterolateral fusion or interbody fusion with Trinity Elite, according to a news release. Patients' clinical pain outcomes and readiographic fusion status were assessed. At 12 months, 98.6 percent fusion was evaluated by the presence of bridging bone on CT scans.
"The results of this publication support Trinity Elite as a safe and efficacious alternative to autograft for patients undergoing lumbar fusion procedures and demonstrate the compelling benefits of this cellular bone allograft," Kevin Kenny, Orthofix president of global spine, said in the release.
Trinity Elite is a cryopreserved allograft from donor bone that provides an osteoconductive scaffold, inherent osteoinductive growth factors and osteogenic cells for fusion.